Rebalance into DKNG or keep cash until merger clarity?
If the deal stalls, Kalshi’s private valuation could drop; if it goes through, DKNG gets a big boost. I’m watching for catalysts before sizing up.
Another merger headline, no clear timeline or pricing.
Feels like a classic tug-of-war: GLD's 1.4% pop on Friday was nice, but SLV's 0.8% underperformed. Holdings look balanced, yet the 20-day/50-day divergence and 0.3% weekly drawdown keep me cautious. Not chasing.
Are we sure this isn't just ETF rotation? If real yields rise again, why would either hold up? What's the real catalyst?
SLV lagging GLD; small bounce looks crowded.
I’m oddly calm; this looks like a buying opportunity.
Feels like another headline bounce. Chips popping while the rest of the index lags usually means weakness elsewhere. If $RSP can't reclaim Monday’s highs, this rally probably fades fast.
So chips popped, but the index still looks weak?
Single-digit drop? Feels like hype, not inevitability.
If ENPH keeps bleeding, next support looks near 100. Watching for a gap-fill bounce or fade-the-fear squeeze.
Rebalancing away from biotech teens, adding cash.
The volume spike on $TTWO is interesting: 12.7M shares traded today versus ~4.3M average weekly, with 21% above VWAP. Institutional flows show $12.8M inflow; if this holds, next catalyst is likely the Q3 earnings and guidance.
Business fundamentals matter more than today’s volume surge.
